Apyx Medical Corporation (APYX)
Stock Price:
$7.79 USD
0.37 (4.99%)
Updated December 2, 4:00 PM EST - Market closed
Key Info
| Market Cap |
267.00M |
| Revenue (ttm) |
24.71M |
| Net Income (ttm) |
-16.18M |
| Shares Out |
34.22M |
| EPS (ttm) |
-0.46 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
December 2 |
| Last Price |
$7.79 |
| Previous Close |
$7.42 |
| Change ($) |
0.37 |
| Change (%) |
4.99% |
| Day's Open |
7.40 |
| Day's Range |
7.35 - 7.90 |
| Day's Volume |
37,428 |
| 52-Week Range |
2.87 - 8.51 |
More Stats
| Market Cap |
267.00M |
| Enterprise Value |
224.49M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.22M |
| Float |
n/a |
| EPS (basic) |
-0.48 |
| EPS (diluted) |
-0.46 |
| FCF / Share |
-0.55 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
510,085 |
| Short Ratio |
9.76 |
| Short % of Float |
n/a |
| Beta |
0.59 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
10.81 |
| PB Ratio |
4.13 |
| Revenue |
24.71M |
| Operating Income |
-23.96M |
| Net Income |
-16.18M |
| Free Cash Flow |
-18.85M |
| Net Cash |
42.51M |
| Net Cash / Share |
1.24 |
| Gross Margin |
77.53% |
| Operating Margin |
-96.98% |
| Profit Margin |
-65.50% |
| FCF Margin |
-76.28% |
| ROA |
-18.47% |
| ROE |
-22.41% |
| ROIC |
-114.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$8.75*
(12.32% upside)
Low
7.00
Current: $7.79
High
12.00
Target: 8.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 28.24 | 16.61 | 10.23 | 8.82 | 29.52 | 27.68 | 23.66 | 27.67 | 25.41 | 24.23 |
| Revenue Growth | 70.04% | 62.25% | 16.04% | -70.13% | 6.64% | 16.99% | -14.5% | 8.89% | 4.87% | - |
| Gross Profit | 19.09 | 10.83 | 6.96 | 5.12 | 12.56 | 8.99 | 9.20 | 11.33 | 10.73 | 9.99 |
| Operating Income | -20.87 | -14.28 | -13.89 | -11.39 | -6.99 | -5.85 | -3.67 | 1.05 | -0.02 | -2.75 |
| Net Income | -19.71 | 62.72 | -5.06 | -3.95 | 8.59 | -17.28 | -4.34 | 0.62 | 0.11 | -1.54 |
| Shares Outstanding | 34.07 | 33.19 | 31.42 | 27.43 | 24.33 | 17.76 | 17.67 | 17.63 | 17.60 | 17.37 |
| Earnings Per Share | -0.58 | 1.83 | -0.17 | -0.14 | 0.24 | -1.03 | -0.40 | 0.03 | 0.01 | -0.09 |
| EPS Growth | - | - | - | - | - | - | - | 200% | - | - |
| Operating Cash Flow | -18.48 | -20.88 | -3.70 | -2.84 | -5.79 | -0.42 | -2.54 | 0.17 | 1.90 | -0.53 |
| Capital Expenditures | -1.30 | -0.36 | -0.62 | -0.29 | -0.42 | -0.63 | -0.59 | -0.75 | -0.54 | 0.43 |
| Free Cash Flow | -19.78 | -21.24 | -4.33 | -3.12 | -6.21 | -1.05 | -3.12 | -0.59 | 1.36 | -0.09 |
| Cash & Equivalents | 58.81 | 78.35 | 10.76 | 15.34 | 12.77 | 6.63 | 7.92 | 4.16 | 4.88 | 3.83 |
| Total Debt | 1.13 | 0.14 | 2.83 | 3.07 | 3.31 | 3.41 | 3.26 | 3.42 | 3.55 | 3.85 |
| Net Cash / Debt | 57.68 | 78.21 | 7.93 | 12.27 | 9.45 | 3.22 | 4.67 | 0.74 | 1.33 | -0.03 |
| Assets | 84.75 | 95.93 | 30.99 | 35.11 | 31.45 | 24.83 | 33.18 | 28.18 | 28.24 | 27.79 |
| Liabilities | 13.49 | 8.75 | 8.96 | 8.89 | 8.04 | 20.14 | 11.85 | 5.29 | 6.12 | 6.02 |
| Book Value | 71.26 | 87.18 | 22.03 | 26.22 | 23.40 | 1.50 | 19.07 | 22.90 | 22.12 | 21.77 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Apyx Medical Corporation |
| Country |
United States |
| Employees |
266 |
| CEO |
Robert Gershon |
Stock Information
| Ticker Symbol |
APYX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: APYX |
| IPO Date |
January 1, 1987 |
Description
Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company's Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the J-Plasma system allows surgeons to operate in eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.